Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program

This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2010
Materias:	type 2 diabetes mellitus dpp-4 inhibitor sitagliptin metformin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/885e51dbaa8b4003872f07898896a2a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:885e51dbaa8b4003872f07898896a2a0
record_format	dspace
spelling	oai:doaj.org-article:885e51dbaa8b4003872f07898896a2a02021-11-14T09:00:15ZExperience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program2072-03512072-037810.14341/2072-0351-5489https://doaj.org/article/885e51dbaa8b4003872f07898896a2a02010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5489https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet and metformin monotherapy. They were transferred to the combined treatment with sitagliptin and metformin during 6 months. The mainend-points assessed in the study were hypoglycemic efficiency, frequency of side-effects, and satisfaction of patients and physicians with the treatment.The target HbA1c levelMarina Vladimirovna ShestakovaEndocrinology Research Centrearticletype 2 diabetes mellitusdpp-4 inhibitorsitagliptinmetforminNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 57-60 (2010)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus dpp-4 inhibitor sitagliptin metformin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus dpp-4 inhibitor sitagliptin metformin Nutritional diseases. Deficiency diseases RC620-627 Marina Vladimirovna Shestakova Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
description	This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet and metformin monotherapy. They were transferred to the combined treatment with sitagliptin and metformin during 6 months. The mainend-points assessed in the study were hypoglycemic efficiency, frequency of side-effects, and satisfaction of patients and physicians with the treatment.The target HbA1c level
format	article
author	Marina Vladimirovna Shestakova
author_facet	Marina Vladimirovna Shestakova
author_sort	Marina Vladimirovna Shestakova
title	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
title_short	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
title_full	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
title_fullStr	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
title_full_unstemmed	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
title_sort	experience with sitagliptin (the first dpp-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the russian federation:results of the dia-da observation program
publisher	Endocrinology Research Centre
publishDate	2010
url	https://doaj.org/article/885e51dbaa8b4003872f07898896a2a0
work_keys_str_mv	AT marinavladimirovnashestakova experiencewithsitagliptinthefirstdpp4inhibitorapplicationtothetreatmentoftype2diabetesmellitusintherussianfederationresultsofthediadaobservationprogram
_version_	1718429666842247168

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program

Ejemplares similares